AI Engines For more Details: Perplexity Kagi Labs You
Digestive health: Dextrin is a soluble fiber, meaning it dissolves in water and forms a gel-like substance in the digestive tract. As such, it can add bulk to stool and promote regular bowel movements, which can help alleviate symptoms of constipation and support overall digestive health. Additionally, dextrin may act as a prebiotic, serving as food for beneficial bacteria in the gut and promoting their growth and activity. This can contribute to a healthy balance of gut flora and improved gut health.
Blood sugar control: As a soluble fiber, dextrin can slow down the absorption of carbohydrates from the digestive tract into the bloodstream. This can help prevent rapid spikes in blood sugar levels after meals and improve insulin sensitivity, making it beneficial for individuals with diabetes or insulin resistance. Consuming foods or supplements containing dextrin may contribute to better blood sugar control and reduced risk of complications associated with diabetes.
Weight management: Dextrin can contribute to feelings of fullness and satiety when consumed as part of a meal or snack. By delaying gastric emptying and increasing the release of satiety hormones, dextrin may help control appetite and reduce calorie intake, which can support weight loss or weight management efforts. Including foods or supplements containing dextrin in a balanced diet may aid in achieving and maintaining a healthy weight.
Gut microbiota: Dextrin, particularly certain types such as resistant dextrin, can serve as a substrate for the growth and activity of beneficial bacteria in the gut. By promoting the proliferation of probiotic bacteria, dextrin may help maintain a diverse and healthy gut microbiota, which is essential for digestion, nutrient absorption, immune function, and overall health.
Cholesterol management: Some research suggests that certain types of dextrin, such as resistant dextrin, may have cholesterol-lowering effects. By binding to bile acids in the intestines and inhibiting their reabsorption, dextrin can help lower LDL (bad) cholesterol levels and reduce the risk of heart disease. Consuming foods or supplements containing dextrin may contribute to improved cholesterol levels and cardiovascular health.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium bifidum | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium catenulatum | Reduces |
species | Bifidobacterium longum | Reduces |
species | Bifidobacterium pseudocatenulatum | Reduces |
species | Lactobacillus acidophilus | Reduces |
species | Lactobacillus crispatus | Reduces |
species | Lactobacillus gasseri | Reduces |
species | Lactobacillus helveticus | Reduces |
species | Lactobacillus jensenii | Reduces |
species | Lactobacillus johnsonii | Reduces |
species | Lactobacillus kefiranofaciens | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | 1 | -2.33 |
ADHD | 1.1 | 1.1 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.9 | 0.9 | |
Allergic Rhinitis (Hay Fever) | 2.1 | -2.1 | |
Allergies | 0.8 | 1.2 | -0.5 |
Allergy to milk products | 0.6 | 1 | -0.67 |
Alopecia (Hair Loss) | 1.3 | -1.3 | |
Alzheimer's disease | 1.4 | 1.1 | 0.27 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.3 | 3.33 |
Ankylosing spondylitis | 0.8 | 1.6 | -1 |
Anorexia Nervosa | 0.9 | 0.6 | 0.5 |
Asthma | 0.5 | 0.3 | 0.67 |
Atherosclerosis | 1 | 1 | |
Atrial fibrillation | 1.6 | 1.7 | -0.06 |
Autism | 2.5 | 2.2 | 0.14 |
Bipolar Disorder | 0.6 | -0.6 | |
Brain Trauma | 0.5 | 0.5 | 0 |
Carcinoma | 1.7 | 1.7 | 0 |
Celiac Disease | 1.9 | 1.3 | 0.46 |
Cerebral Palsy | 1.1 | 1.1 | |
Chronic Fatigue Syndrome | 1.4 | 1 | 0.4 |
Chronic Kidney Disease | 0.3 | 1.1 | -2.67 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
Coagulation / Micro clot triggering bacteria | 0.6 | 0.6 | 0 |
Colorectal Cancer | 0.7 | 1.4 | -1 |
Constipation | 0.6 | 0.6 | 0 |
Coronary artery disease | 0.9 | 0.3 | 2 |
COVID-19 | 2.6 | 3.4 | -0.31 |
Crohn's Disease | 2.7 | 2.4 | 0.13 |
cystic fibrosis | 0.5 | -0.5 | |
Depression | 3.7 | 3.2 | 0.16 |
Dermatomyositis | 0.5 | -0.5 | |
Eczema | 0.5 | -0.5 | |
Endometriosis | 0.5 | 1.7 | -2.4 |
Epilepsy | 2.2 | 1.9 | 0.16 |
erectile dysfunction | 0.3 | -0.3 | |
Fibromyalgia | 0.5 | 2.8 | -4.6 |
Functional constipation / chronic idiopathic constipation | 0.9 | 2.2 | -1.44 |
gallstone disease (gsd) | 1.7 | -1.7 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.2 | 1 |
Generalized anxiety disorder | 1.3 | -1.3 | |
Glioblastoma | 0.3 | 0.3 | |
Gout | 0.3 | 0.3 | |
Graves' disease | 1.9 | 0.9 | 1.11 |
Hashimoto's thyroiditis | 0.5 | 1.4 | -1.8 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.4 | 1.4 | |
hyperglycemia | 1.2 | 1.6 | -0.33 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0.5 | 0 |
hypersomnia | 0.6 | 0.6 | |
hypertension (High Blood Pressure | 1.9 | 1.6 | 0.19 |
Hypothyroidism | 0.9 | 0.5 | 0.8 |
Hypoxia | 0.5 | 0.6 | -0.2 |
IgA nephropathy (IgAN) | 1.3 | -1.3 | |
Inflammatory Bowel Disease | 1.8 | 1.2 | 0.5 |
Insomnia | 0.7 | 0.6 | 0.17 |
Intelligence | 0.3 | -0.3 | |
Intracranial aneurysms | 1.7 | -1.7 | |
Irritable Bowel Syndrome | 1.9 | 1.3 | 0.46 |
Liver Cirrhosis | 1 | 2.5 | -1.5 |
Long COVID | 3.2 | 3 | 0.07 |
Low bone mineral density | 0.3 | 0.3 | |
Lung Cancer | 1.2 | 1.2 | |
ME/CFS with IBS | 0.2 | 0.5 | -1.5 |
ME/CFS without IBS | 0.2 | 0.5 | -1.5 |
Menopause | 0.3 | 0.2 | 0.5 |
Metabolic Syndrome | 2.8 | 3 | -0.07 |
Mood Disorders | 3.9 | 3.2 | 0.22 |
multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
Multiple Sclerosis | 2.3 | 1.9 | 0.21 |
Multiple system atrophy (MSA) | 1.1 | 0.7 | 0.57 |
Neuropathy (all types) | 0.5 | 0.9 | -0.8 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 1.6 | -0.45 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 2.5 | 2.1 | 0.19 |
obsessive-compulsive disorder | 0.9 | 2 | -1.22 |
Osteoarthritis | 0.5 | -0.5 | |
Osteoporosis | 1.1 | 0.5 | 1.2 |
Parkinson's Disease | 2.5 | 1.4 | 0.79 |
Polycystic ovary syndrome | 0.5 | 2 | -3 |
Postural orthostatic tachycardia syndrome | 0.5 | -0.5 | |
Premenstrual dysphoric disorder | 1.1 | 0.6 | 0.83 |
primary biliary cholangitis | 0.3 | -0.3 | |
Psoriasis | 1.8 | 0.6 | 2 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 2.5 | -0.67 |
Rosacea | 0.5 | 0.5 | 0 |
Schizophrenia | 2.1 | 1.4 | 0.5 |
scoliosis | 0.3 | -0.3 | |
sensorineural hearing loss | 0.3 | 0.3 | |
Sjögren syndrome | 1.7 | 1.9 | -0.12 |
Sleep Apnea | 1.1 | 0.6 | 0.83 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | -0.2 | |
Stress / posttraumatic stress disorder | 1.3 | 1.1 | 0.18 |
Systemic Lupus Erythematosus | 1.4 | 2.2 | -0.57 |
Tic Disorder | 0.5 | -0.5 | |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 1.7 | -1.7 | |
Type 2 Diabetes | 2.5 | 2.5 | 0 |
Ulcerative colitis | 2.1 | 1.3 | 0.62 |
Unhealthy Ageing | 0.5 | 0.7 | -0.4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.